Sarin P S, Talmadge J E, Heseltine P, Murcar N, Gendelman H E, Coleman R, Kelsey L, Beckner S, Winship D, Kahn J
CEL-SCI Corporation, Vienna, VA 22182, USA.
Vaccine. 1999 Jan;17(1):64-71. doi: 10.1016/s0264-410x(98)00119-4.
Eleven HIV-1 seronegative subjects previously injected with an HIV-1 p17 synthetic peptide vaccine (HGP-30) were given two booster immunizations to evaluate memory cell responses and the ability to boost cellular and humoral immune responses. Five of 11 subjects showed a significant increase in their antibody titres to HGP-30 or p17 and 6/11 had T-cell proliferation responses to either HGP-30 or p17. HIV-1 virus challenge studies in SCID mice demonstrated that 39 of 50 mice (78%) receiving PBMC from 5 of the HGP-30 immunized subjects were protected from infection with a different strain of HIV-1 compared to 4 of 30 mice (13%) that received PBMC from 3 non-immunized subjects (p < 0.001). These studies show that booster immunizations with HGP-30 vaccine are safe and non-toxic and induce protective cell mediated immune responses.
